Combined phototherapeutic keratectomy and therapeutic contact lens for recurrent erosions in bullous keratopathy

Pei-Yu Lin, Chih-Chiau Wu, Shui-Mei Lee

Abstract

Aims—To evaluate the therapeutic effects of excimer laser phototherapeutic keratectomy (PTK) combined with therapeutic contact lenses for painful recurrent corneal erosions (RCE) secondary to bullous keratopathy (BK) not suitable for penetrating keratoplasty.

Methods—Excimer laser PTK was performed prospectively in eight eyes with painful RCE due to BK visually expecting no benefit from penetrating keratoplasty. After mechanical removal of the epithelium, the corneas were ablated with 50 pulses in the central 6.5 mm zone (ablation rate 0.25 µm per pulse) and another 200 pulses for polishing the periphery. After PTK, therapeutic contact lenses were applied for 3 months. The mean follow-up period after PTK was 10.9 months (ranging from 6 to 15 months).

Results—All patients experienced relief of their pain symptoms after the epithelium healed. Only one patient complained of occasional stinging pain with intermittent recurrence of small bullae. He refused a second treatment because the pain was much less than that before the surgery and quite tolerable. No infection or other complications were noted.

Conclusion—PTK with deeper ablation and adjunctive therapeutic contact lens is an easy to perform and effective treatment with less recurrence rate for patients with BK and poor visual potential.

(Br J Ophthalmol 2001;85:908–911)

The best treatment of choice for bullous keratopathy (BK) with painful recurrent corneal erosions (RCE) is penetrating keratoplasty. But in cases not suitable for penetrating keratoplasty or the visual potential is poor the treatment goal is to relieve patients of pain with methods including Gunderson’s conjunctival flap surgery,1–2 bandage contact lens,3–4 epikeratophakia,5 anterior stromal puncture,6 excimer laser phototherapeutic keratectomy (PTK),7–8 annular keratotomy,9 and amniotic membrane transplantation.10 PTK has been successfully used in the treatment of RCE11–20 caused by varied aetiologies. The recurrence rate ranged from 0% to 26% after a single treatment. In 1995 Thomann et al11 reported using PTK to treat patients with RCE due to BK with promising effect. However, in around 77% of the patients, bullae persisted weeks after the treatment. Although bullae became rare in most patients after 1–2 months, in five of 13 (38.5%) patients, a second treatment was necessary because of persistent pain. In 1994, we performed PTK with ablation depth of 5 µm after removal of the epithelium in two cases of RCE due to BK. After initial epithelial healing and relief of symptoms in 4 days, both of them showed recurrence of bullae and epithelial erosion in 10 days (Fig 1). The underlying endothelial decompensation was thought to be the aetiology of recurrent bullae formation. And because of the subepithelial fluid accumulation, the process of epithelial adhesion to the Bowman’s membrane was interrupted, which was probably one of the reasons for the higher recurrence rate.

It is generally accepted that the ablation depth of PTK for RCE is limited within the Bowman’s layer to prevent stromal haze formation. But in cases of BK with poor visual potential, the treatment goal is to relieve pain. In clinical experience the epithelium-stroma adhesion with haze formation seen in photorefractive keratectomy (PRK) seldom gives rise to RCE. So PTK with ablation depth beyond the Bowman’s layer may probably promote tighter epithelial adhesion and consequently will provide benefit if not disturbing the already poor vision. This study was designed to
evaluate the effect of PTK with deeper ablation and adjunctive postoperative therapeutic contact lens to prevent early bullae recurrence in the treatment of painful RCE due to BK.

**Patients and methods**

Between April 1999 and January 2000 we performed PTK on eight eyes of eight patients with recalcitrant painful RCE due to BK of varying aetiologies (Table 1). The mean follow up period was 10.9 (ranging from 6 to 15) months. After thorough discussion with the patients, corneal transplantation was not considered because of their poor visual potential. Every patient had a complete ophthalmic examination before the treatment and was followed up regularly postoperatively.

All therapy was performed with the Summit SVS Apex Plus excimer laser (193 nm, 180 mJ/cm², ablation rate 0.25 µm per pulse, pulse frequency 10 Hz) using PTK mode. Under topical anaesthesia, the whole epithelium except that close to the limbus was removed easily with a No 64 Beaver blade or Weckcell. The central 6.5 mm optic zone was ablated with 50 pulses. Then the already ablated area was protected with 2% methylcellulose. The peripheral ring was polished with another 200 pulses of diameter 2–3 mm in an annular fashion by rotating the patient’s head smoothly.

**Results**

All patients experienced relief of their pain after the epithelium healed, which took 3–4 days. No recurrence of bullae or pain was observed in all patients with the contact lens in position and remained so in seven patients after removal of the contact lens. Anterior stromal haze similar to that seen after PRK for myopia was noted after 2–3 months. After removal of the contact lens, one patient complained of occasional stinging pain with intermittent recurrence of small bullae (Fig 2). He refused a second treatment because the pain was much less than that before the surgery and was quite tolerable.

Although all patients had very poor visual potential, slight improvement in vision was shown in three patients (Table 1). No patient experienced deterioration of vision. Two patients complained of a sticky sensation that could be partially relieved with lubricant eye drops. No infection or other complications were noted.

**Discussion**

Three issues are involved in the treatment of RCE due to BK. Firstly, should the treatment zone be restricted to the affected area or extended to the entire cornea? Secondly, should the ablation depth be limited.

**Table 1  Patient data**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Follow up period (months)</th>
<th>Associated diseases</th>
<th>Preop VA</th>
<th>Postop VA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>72</td>
<td>M</td>
<td>15</td>
<td>Glaucoma</td>
<td>NLP</td>
<td>NLP</td>
</tr>
<tr>
<td>2</td>
<td>68</td>
<td>M</td>
<td>14</td>
<td>Glaucoma</td>
<td>HM</td>
<td>CF</td>
</tr>
<tr>
<td>3</td>
<td>63</td>
<td>F</td>
<td>13</td>
<td>RD</td>
<td>HM</td>
<td>HM</td>
</tr>
<tr>
<td>4</td>
<td>61</td>
<td>F</td>
<td>12</td>
<td>Glaucoma</td>
<td>LP</td>
<td>HM</td>
</tr>
<tr>
<td>5</td>
<td>66</td>
<td>M</td>
<td>6</td>
<td>ARMD</td>
<td>HM</td>
<td>CF</td>
</tr>
<tr>
<td>6</td>
<td>67</td>
<td>F</td>
<td>12</td>
<td>Glaucoma</td>
<td>CF</td>
<td>CF</td>
</tr>
<tr>
<td>7</td>
<td>81</td>
<td>F</td>
<td>9</td>
<td>PDR</td>
<td>CF</td>
<td>CF</td>
</tr>
<tr>
<td>8</td>
<td>74</td>
<td>M</td>
<td>6</td>
<td>Glaucoma</td>
<td>HM</td>
<td>HM</td>
</tr>
</tbody>
</table>

After PTK, a therapeutic contact lens was applied immediately and exchanged every 2–3 weeks for 3 months together with topical antibiotics (0.25% chloramphenicol). Non-preserved artificial tears (Refresh, Allergan) and antiglaucoma medications were used when necessary. No topical corticosteroids were given. All patients were treated only once.
within the Bowman’s layer? Thirdly, should therapeutic contact lenses be used and for how long? There are several reports on the treatment of RCE with PTK.11–20 Most of them restricted the treatment zone to the affected area. For our cases of RCE, the whole epithelium was very loosely attached to the underlying Bowman’s layer. Then, should recalcitrant RCE be treated extensively? Kaplan-Messas et al21 reported a study that compared a focal mode of treatment with a diffuse mode for RCE. Two eyes with focal PTK, but no eye with diffuse PTK had recurrent erosions after a mean follow up of 8.0 and 9.0 months, respectively. Kreimer et al22 combined PRK and PTK to treat 16 myopic eyes with recalcitrant RCE. Following total epithelial scraping, PRK was performed at a central 6.0 mm zone. Then, confluent 3.0 mm zones of PTK were ablated at a depth of 6.0 µm, surrounding the zone of PRK. There was no recurrence during the follow up period, which ranged from 26 to 42 months. In Thomann et al’s study8 of PTK for RCE in BK, only the bullous area was treated. They did not mention whether the recurrent bullae were located inside or outside the treatment zone. But for BK, the bullae will change position from time to time. It is suggested that RCE especially in BK is a diffuse disease, and therefore extensive ablation may be more desirable for prevention of recurrence.

In order to prevent hyperopic shift and corneal haze, the ablation depths of PTK for RCE are usually limited within the Bowman’s layer. But for patients with BK with poor visual potential, the treatment goal is to relieve pain by enhancing epithelial adhesion. In the patients who are re-treated after PRK with regress and haze, the epithelium appears to be more firmly adherent to the underlying ablated zone and the anterior stromal surface becomes more irregular.14,25 Marshall et al26 noted discontinuities of the basement membrane in the laser ablated area with the resultant micro-excision of stroma anteriorly and epithelium posteriorly. The solid haze that developed in the anterior stroma after PRK or PTK is due to collagen deposits produced by myofibroblast.27,28 Although no conclusion can be drawn from these observations concerning the strength of adhesion between epithelium and stroma in the absence of the Bowman’s layer, clinical experience shows that superficial keratectomy rarely gives rise to RCE postoperatively.27 Accordingly, one might expect at least normal, if not stronger, strength of adhesion between the epithelium and the stroma with the Bowman’s layer ablated and haze developed.

It is suggested that at least 2 months are required for the treatment of RCE.29 Animal studies show that the adhesion complex between corneal epithelium and stroma is restored 6–8 weeks after injury.29,30 In Thomann et al’s study,17 77% of patients who received PTK for RCE due to BK showed persistence of bullae for 1–2 months postoperatively. This coincides with the time for adhesion complex formation. Because of the underlying endothelial decompensation, fluid will re-accumulate beneath the epithelium after the epithelium is healed but not yet adherent to the stroma. Application of therapeutic contact lenses during this period can prevent bullae recurrence31 that might interfere with adhesion complex formation. According to SundarRaj et al’s report,31 for rhesus monkeys receiving excimer laser keratectomy, the re-establishment of a nearly continuous anchoring fibril zone was evident after 12 weeks. Our patients wore therapeutic contact lenses for 3 months and no RCE was suffered when the contact lenses were in place. However, the exact time required for human adhesion complex formation of the long term laser ablation, especially in cases of BK, remains to be explored. Because most of our patients had a history of multiple surgery and consequently unstable tear film, long term contact lens wearing may lead to the hazard of infectious keratitis. So we limit the contact lens wearing time to 3 months and none of our patients had infection.

This preliminary report demonstrates that the methods we used for relieving symptoms of BK is easy to perform and highly effective with low recurrence rate. However, longer follow up is required for evaluation of the long term effectiveness. And more research, especially ultrastructural studies, is needed before any conclusion can be drawn about the epithelial adhesion strength in conditions of different excimer laser ablation depth and the effects of therapeutic contact lens on anchoring complex formation for cases of BK.

Contributors please note:

Communications from all countries except the UK and Republic of Ireland should be sent to Professor C Hoyt, Editor, British Journal of Ophthalmology, University of California, Department of Ophthalmology, 10 Kirkham Street, K 301, San Francisco, CA 94143-0730, USA (tel: 001 415 502-6871; fax: 001 415 514-1521).

Manuscripts from the UK and the Republic of Ireland should be sent to Professor Andrew Dick, UK Editor, British Journal of Ophthalmology, Division of Ophthalmology, University of Bristol, Lower Maudlin Street, Bristol BS1 2LX (tel: +44 (0) 0117 929-4496; fax: +44 (0) 0117 929-4607).